Congratulations to the Sentara team members
Congratulations to the Sentara team members who successfully completed our first patient procedure in the recently approved SPHERE PerAF Trial! This clinical trial will evaluate the safety and effectiveness of the Affera system and Sphere-9 catheter for the treatment of Persistent Atrial Fibrillation (AFib). This new investigational ablation technique uses pulsed-field energy instead of thermal energy.
AFib is the most common type of irregular heartbeat that often causes the heart to beat too quickly. People with AFib are five times more likely to suffer a stroke, so it’s critically important to be able to quickly identify and treat AFib before it leads to worsening symptoms.
The SPHERE PerAF trial uses pulsed field ablation to normalize an irregular heartbeat and is the first randomized catheter ablation IDE trial to treat persistent atrial fibrillation. The trial compares a conventional radiofrequency ablation catheter to the Sphere-9™ catheter which is capable of delivering energy with a larger ablative footprint to facilitate lesion overlap and procedural efficiency. You can learn more about this clinical trial and the great work being done by the Sentara Health Research Center here: https://bit.ly/3vB9A2r.
Original source can be found here
Alerts Sign-up